Karyopharm Therapeutics (KPTI)
Commercializer of the XPO1 inhibitor selinexor for blood cancers.
$1.78
Pre-market0.00 (0.00%)
At close$1.78(−3.78%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions100 holders · as of Mar 31, 2026 · largest filers plus last quarter's tail | ≈ 77.52% | 17.58M shares | |
| Insiders14 holders · as of Sep 2, 2026 | 3.77% | 855.5K shares | |
| Otherremainder | ≈ 18.71% | 4.24M shares |
22.68M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Institutions13F, as of Mar 31, 2026
100 holders · 17.58M shares · 29 new positions · 63 increased · 9 reduced · 16 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Commodore Capital LP | 1.95M | 8.60% | +1.95Mnew | May 15, 2026 |
| Ra Capital Management, L.P. | 1.92M | 8.45% | +1.92Mnew | May 15, 2026 |
| Adage Capital Partners GP, L.L.C. | 1.81M | 7.96% | +1.39M | May 15, 2026 |
| T. Rowe Price Investment Management, Inc. | 1.54M | 6.80% | +50.7K | May 15, 2026 |
| Goldman Sachs Group Inc | 947.6K | 4.18% | +947.6K | May 15, 2026 |
| Catalio Capital Management, LP | 897.7K | 3.96% | +754.7K | May 15, 2026 |
| Vanguard Capital Management LLC | 739.7K | 3.26% | +739.7Knew | May 15, 2026 |
| Ikarian Capital, LLC | 733.4K | 3.23% | +188.9K | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Commodore Capital LP | 9.90% | 1.95M | 13G | Apr 2, 2026 ↗ |
| RA Capital Management, L.P. | 9.90% | 2.08M | 13G | Apr 2, 2026 ↗ |
| Affinity Asset Advisors, LLC | 8.60% | 2.07M | 13G | May 14, 2026 ↗ |
| Adage Capital Management, L.P. | 8.08% | 1.82M | 13G | May 13, 2026 ↗ |
| Affinity Healthcare Fund, LP | 7.83% | 664.2K | 13G | Apr 10, 2025 ↗ |
| Highbridge Capital Management, LLC | 7.20% | 13G | Oct 25, 2024 ↗ | |
| T. Rowe Price Investment Management, Inc. | 6.60% | 1.54M | 13G | Jun 5, 2026 ↗ |
| BlackRock, Inc. | 5.60% | 1.27M | 13G | Jul 28, 2026 ↗ |
| The Goldman Sachs Group, Inc. | 5.10% | 991.4K | 13G | May 12, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 1, 2026 | Kristin Abateofficer: Chief Accounting Officer | Sale | 19 | $2.02 | 23,782 |
| Jul 28, 2026 | Stuart Poultonofficer: EVP, Chief Development Officer | Sale | 189 | $7.10 | 94,632 |
| May 14, 2026 | Michael Manoofficer: EVP, CLO&Secretary | Sale | 266 | $9.50 | 94,398 |
| May 14, 2026 | Richard A. Paulsondirector, officer: President and CEO | Sale | 2,203 | $9.50 | 269,747 |
| May 14, 2026 | Kristin Abateofficer: Chief Accounting Officer | Sale | 53 | $9.50 | 23,801 |
| May 14, 2026 | Sohanya Roshan Chengofficer: EVP & Chief Commercial Officer | Sale | 324 | $9.50 | 107,940 |
| May 14, 2026 | Reshma Rangwalaofficer: EVP & Chief Medical Officer | Sale | 408 | $9.50 | 56,829 |
| May 14, 2026 | Stuart Poultonofficer: EVP, Chief Development Officer | Sale | 403 | $9.50 | 94,821 |
| Apr 21, 2026 | Reshma Rangwalaofficer: EVP & Chief Medical Officer | Sale | 449 | $8.94 | 56,290 |
| Mar 2, 2026 | Stuart Poultonofficer: EVP, Chief Development Officer | Sale | 5,101 | $9.41 | 94,328 |
CongressHouse and Senate disclosures
Not reported.